The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2019 | Managing post-transplant relapse in AML
A major area of unmet clinical need is the management of patients that relapse post-transplant in acute myeloid leukemia (AML). Here, Charles Craddock, CBE, FRCP(UK), FRCPath, DPhil, of the University of Birmingham, Birmingham, UK, discusses the therapeutic options that can help address this unmet need. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.
